Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 11;148(1):58-69.
doi: 10.1093/bmb/ldad023.

Small interfering RNAs in the management of human osteoporosis

Giuseppe Gargano  1   2   3 , Giovanni Asparago  1   2 , Filippo Spiezia  3 , Francesco Oliva  1   2 , Nicola Maffulli  4   5   6
Affiliations
Review

Small interfering RNAs in the management of human osteoporosis

Giuseppe Gargano et al. Br Med Bull. .

Abstract

Background: Osteoporosis results in reduced bone mass and consequent bone fragility. Small interfering RNAs (siRNAs) can be used for therapeutic purposes, as molecular targets or as useful markers to test new therapies.

Sources of data: A systematic search of different databases to May 2023 was performed to define the role of siRNAs in osteoporosis therapy. Fourteen suitable studies were identified.

Areas of agreement: SiRNAs may be useful in studying metabolic processes in osteoporosis and identify possible therapeutic targets for novel drug therapies.

Areas of controversy: The metabolic processes of osteoporosis are regulated by many genes and cytokines that can be targeted by siRNAs. However, it is not easy to predict whether the in vitro responses of the studied siRNAs and drugs are applicable in vivo.

Growing points: Metabolic processes can be affected by the effect of gene dysregulation mediated by siRNAs on various growth factors.

Areas timely for developing research: Despite the predictability of pharmacological response of siRNA in vitro, similar responses cannot be expected in vivo.

Keywords: RNA interference; RNA silencing; osteoporosis; osteoporosis therapy; short interfering RNA; small interfering RNA.

PubMed Disclaimer

Conflict of interest statement

Authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Mechanism to degrade the messenger wire.
Fig. 2
Fig. 2
PRISMA flow diagram.
Fig. 3
Fig. 3
Osteoporosis treatment.
See this image and copyright information in PMC

References

    1. Migliorini F, Giorgino R, Hildebrand F, et al. Fragility fractures: risk factors and Management in the Elderly. Medicina (Kaunas) 2021;57:1119. - PMC - PubMed
    1. Migliorini F, Cuozzo F, Torsiello E, et al. Autologous bone grafting in trauma and orthopaedic surgery: an evidence-based narrative review. J Clin Med 2021;10:4347. - PMC - PubMed
    1. Sinha A, Robertson G, Maffulli N. Doctor, I fractured my ankle. When can I return to play? An updated systematic review. Br Med Bull 2022;143:35–45. - PMC - PubMed
    1. Marsillo E, Pintore A, Asparago G, et al. Cephalomedullary nailing for reverse oblique intertrochanteric fractures 31A3 (AO/OTA). Orthop Rev 2022;14:38560. - PMC - PubMed
    1. Migliorini F, Maffulli N, Spiezia F, et al. Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. J Orthop Surg 2021;16:318. - PMC - PubMed

MeSH terms

Substances